Get the Stockscreener App
2.17
3.77%
-0.085
After Hours:
2.17
Allogene Therapeutics Inc stock is traded at $2.17, with a volume of 4.87M.
It is down -3.77% in the last 24 hours and up +17.93% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$2.255
Open:
$2.35
24h Volume:
4.87M
Relative Volume:
1.00
Market Cap:
$454.99M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-1.0236
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
+6.37%
1M Performance:
+17.93%
6M Performance:
-20.80%
1Y Performance:
-51.13%
1-Day Range:
$2.14
$2.39
1-Week Range:
$2.14
$3.78
52-Week Range:
$1.32
$5.775
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.17 | 454.99M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Insider Sell: Deborah Messemer Sells Shares of Allogene Therapeu - GuruFocus.com
Allogene therapeutics director Deborah Messemer sells $32,350 in stock - Investing.com
Allogene Therapeutics Director Sells Shares Under Trading Plan - TradingView
Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal year - MSN
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - Benzinga
Baird ‘encouraged’ by Allogene CAR-T therapy update - TipRanks
Diffuse Large B-cell Lymphoma Market Expected to rise, 2034 | - openPR
Allogene stock hits 52-week low at $1.76 amid market challenges - Investing.com Nigeria
Allogene leaps on allogeneic CAR-T therapy success - The Pharma Letter
Allogene reports promising results for CAR T therapy in lymphoma - MSN
abrdn plc Invests $776,000 in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene stock plunges to 52-week low at $1.33 amid steep annual decline - Investing.com Nigeria
Allogene Therapeutics Announces Publication of Durable - GlobeNewswire
Allogene reports promising results for CAR T therapy in lymphoma By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Positive Phase 1 Results for Cema-Cel in Treating Relapsed/Refractory Large B-Cell Lymphoma - Nasdaq
Allogene stock plunges to 52-week low at $1.33 amid steep annual decline By Investing.com - Investing.com South Africa
A stock that deserves closer examination: Allogene Therapeutics Inc (ALLO) - US Post News
Ratio Revelations: Allogene Therapeutics Inc (ALLO)’s Financial Metrics in the Spotlight - The Dwinnex
Earl Martin Douglas Sells 6,404 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Sells $25,215.66 in Stock - MarketBeat
Allogene Therapeutics Falls To US$1.51, But Insiders Sold At Lower Price - Simply Wall St
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN
Allogene Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Follicular Lymphoma Pipeline 2024: Comprehensive Clinical - openPR
Allogene Therapeutics Announces Participation in February Investor Conferences - GlobeNewswire
Allogene Therapeutics Joins Elite Biotech Lineup at Major Oppenheimer Conference - StockTitan
Allogene Therapeutics executive to depart, consulting agreement planned - MSN
Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial - CRISPR Medicine News
Allogene Therapeutics, Inc. Announces Departure of Timothy MooreOn January 23, 2025, Allogene Therapeutics, Inc. (NASDAQ: ALLO) revealed in an 8-K filing that Timothy Moore, the Company’s incumbent executive, would be concluding his tenure with the - Defense World
Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News
Cell Therapy Weekly: Phase I Trial for Autoimmune CAR-T Therapy - RegMedNet
Allogene Therapeutics executive to depart, consulting agreement planned By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer - BioSpace
Allogene Therapeutics Announces Executive Departure and Transition - TipRanks
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):